NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 26, 2017

Study Completion Date

June 26, 2017

Conditions

Overactive BladderUrinary Urge IncontinenceUrinary Bladder, NeurogenicPainful Bladder Syndrome

Interventions

DRUG

Onabotulinumtoxin A (BoNT)

DRUG

belladonna

Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.

DRUG

Morphine

Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.

DRUG

Placebo

matching placebo to B\&O suppository

DRUG

Active B&O suppository of belladonna

belladonna 16.2mg and morphine 7.5mg

Trial Locations (2)

Wichita Women's Pelvic Surgery Center at Associates in Women's Health, Wichita

University of Kansas School of Medicine - Wichita, Wichita

All Listed Sponsors

lead

Edgar LeClaire, MD

OTHER